Skip to main content
Top
Published in: BMC Clinical Pathology 1/2017

Open Access 01-12-2017 | Research article

Utilizing BD MAX™ Enteric Bacterial Panel to Detect Stool Pathogens from Rectal Swabs

Authors: Barbara DeBurger, Sarah Hanna, Eleanor A. Powell, Cindi Ventrola, Joel E. Mortensen

Published in: BMC Clinical Pathology | Issue 1/2017

Login to get access

Abstract

Background

The BD MAX™ Enteric Bacterial Panel (BDM-EBP) is designed and FDA-cleared to detect Salmonella, Shigella, Campylobacter, and Shiga toxin genes stx1/2 from stool samples. However, rectal swabs, which are not FDA-cleared for clinical testing with the BDM-EBP, are common specimens received from pediatric patients for enteric pathogen testing. The purpose of this study was to evaluate the ability of the BDM-EBP to detect stool pathogens from rectal swabs.

Methods

Routine cultures, Shiga toxin testing, and molecular testing with BDM-EBP were performed on 272 sequential rectal swabs collected from August 2015 to December 2015. Discrepant test results were resolved using Verigene® Enteric Pathogens Nucleic Acid Test (EP). 36 challenge samples (13 Salmonella spp., 3 Shigella spp., 10 Campylobacter spp., and 10 Shiga toxin positive Escherichia coli) were tested using reference strains (American Type Culture Collection) and previous patient isolates diluted to103-104 cfu/ml in saline then added to Sample Buffer Tube (SBT) with negative stool matrix delivered via a swab. Limit of detection testing was performed by serial 10 fold dilutions in saline then added to SBT with negative stool matrix provided via a swab.

Results

A total of 272 rectal swab specimens were evaluated and 89 were positive by culture and/or MAX EBP. All discrepant results were BDM-EBP positive and culture negative. 21 of 31 (68%) of the apparent false positive BDM-EBP discrepant results resolved as positive with Nanosphere’s Verigene® EP. After resolution of the discordant results, the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) are as follows for each target: Salmonella (n = 4) 100%, PPA and 100%, NPA; Shigella (n = 79) 100%, PPA and 95.3%, NPA; Campylobacter (n = 4) 100%, PPA and 99.6%, NPA; and Shiga toxin producing organisms (n = 2) 100%, PPA and 100%, NPA. 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in the challenge samples were detected. Limits of detection for BDM-EBP testing of rectal swabs were as follows (in cfu/ml in SBT): Salmonella-1.44 × 102; Shigella-5.10 × 100; Campylobacter-1.51 × 101; and Shiga Toxin-1.13 ×103.

Conclusion

Rectal swabs are acceptable samples for detecting Salmonella, Shigella, Campylobacter, and Shiga toxin using BDM-EBP.
Literature
1.
go back to reference WHO/UNICEF. Ending preventable child deaths from pneumoniae and diarrhea by 2025: The integrated Global Action Plan for Pneumoniae and Diarrhoeae (GAPPD). New York: The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO); 2013. WHO/UNICEF. Ending preventable child deaths from pneumoniae and diarrhea by 2025: The integrated Global Action Plan for Pneumoniae and Diarrhoeae (GAPPD). New York: The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO); 2013.
2.
go back to reference Johansson EW, Wardlaw T, Binkin N, Brocklehurst C, Dooley T. Diarrhoea: why children are still dying and what can be done, (UNICEF). New York: The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO); 2009. Johansson EW, Wardlaw T, Binkin N, Brocklehurst C, Dooley T. Diarrhoea: why children are still dying and what can be done, (UNICEF). New York: The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO); 2009.
3.
go back to reference Harrington SM, Buchan BW, Doern C, Fader R, Ferraro MJ, Pillai DR, Rychert J, Doyle L, Lainesse A, Karchmer T, Mortensen JE. Multicenter Evaluation of the BD Max™ Enteric Bacterial Panel PCR Assay for Rapid Detection of Salmonella spp., Shigella spp., Campylobacter spp. (C. jejuni and C. coli), and Shiga Toxin 1 and 2 Genes. J Clin Microbiol. 2015;53:1639–46.CrossRefPubMedPubMedCentral Harrington SM, Buchan BW, Doern C, Fader R, Ferraro MJ, Pillai DR, Rychert J, Doyle L, Lainesse A, Karchmer T, Mortensen JE. Multicenter Evaluation of the BD Max™ Enteric Bacterial Panel PCR Assay for Rapid Detection of Salmonella spp., Shigella spp., Campylobacter spp. (C. jejuni and C. coli), and Shiga Toxin 1 and 2 Genes. J Clin Microbiol. 2015;53:1639–46.CrossRefPubMedPubMedCentral
4.
go back to reference Garcia LS, Isenberg HD, Clinical Microbiology Procedures Handbook. 3rd ed. 2010. Washington, DC: ASM Press, pp. 2.1.14, 3.8.1.3, 3.8.1.4. Garcia LS, Isenberg HD, Clinical Microbiology Procedures Handbook. 3rd ed. 2010. Washington, DC: ASM Press, pp. 2.1.14, 3.8.1.3, 3.8.1.4.
5.
go back to reference Jorgensen JH, et al., Manual of Clinical Microbiology. 11th ed. 2015, Washington, DC: ASM Press, pp. 271, 275, 276. Jorgensen JH, et al., Manual of Clinical Microbiology. 11th ed. 2015, Washington, DC: ASM Press, pp. 271, 275, 276.
6.
go back to reference Cloud JL, Hymas W, Carroll K. Impact of Nasopharyngeal Swab Types on Detection of Bordetella pertussis by PCR and Culture. J Clin Microbiol. 2002;40(10):3838–40.CrossRefPubMedPubMedCentral Cloud JL, Hymas W, Carroll K. Impact of Nasopharyngeal Swab Types on Detection of Bordetella pertussis by PCR and Culture. J Clin Microbiol. 2002;40(10):3838–40.CrossRefPubMedPubMedCentral
7.
go back to reference Mortensen JE, Ventrola C, Hanna S, Walter A. Comparison of time-motion analysis of conventional stool culture and the BD MAX™ Enteric Bacterial Panel (EBP). BMC Clin Pathol. 2015;15:9.CrossRefPubMedPubMedCentral Mortensen JE, Ventrola C, Hanna S, Walter A. Comparison of time-motion analysis of conventional stool culture and the BD MAX™ Enteric Bacterial Panel (EBP). BMC Clin Pathol. 2015;15:9.CrossRefPubMedPubMedCentral
Metadata
Title
Utilizing BD MAX™ Enteric Bacterial Panel to Detect Stool Pathogens from Rectal Swabs
Authors
Barbara DeBurger
Sarah Hanna
Eleanor A. Powell
Cindi Ventrola
Joel E. Mortensen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Clinical Pathology / Issue 1/2017
Electronic ISSN: 1472-6890
DOI
https://doi.org/10.1186/s12907-017-0043-2

Other articles of this Issue 1/2017

BMC Clinical Pathology 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.